Faricimab Amino Acid Sequence Patent Details
The patent for the amino acid sequence of faricimab, identified by SEQ ID NO: 14, is U.S. Patent No. 10,975,250 B2 [1].
What does this patent protect?
This patent specifically claims the amino acid sequence of the antibody faricimab. It covers the composition of matter for the antibody itself, which is crucial for its therapeutic function [1]. This means that any entity wishing to produce or sell an antibody with this exact amino acid sequence would need a license to this patent.
When does the patent expire?
U.S. Patent No. 10,975,250 B2 was issued on April 13, 2021 [1]. In the United States, utility patents typically have a term of 20 years from the date on which the application was filed [2]. The filing date for this patent was January 3, 2019, and it claims priority to an earlier filing date of January 5, 2018 [1]. Therefore, the patent is expected to expire in 2038, assuming no extensions or challenges alter its term [1][2].
Who developed faricimab?
Faricimab was developed by Genentech, a member of the Roche Group [3].
What is faricimab used for?
Faricimab is a bispecific antibody that targets angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A) [3]. It is approved for the treatment of neovascular or wet age-related macular degeneration (AMD) and diabetic macular edema (DME) [3]. By neutralizing both Ang-2 and VEGF-A, faricimab aims to stabilize blood vessels and reduce leakage in the retina, addressing the underlying causes of vision loss in these conditions [3].
How does faricimab work?
Faricimab's mechanism of action involves simultaneously inhibiting two key pathways involved in retinal diseases: the VEGF pathway and the angiopoietin pathway [3]. VEGF-A is a major driver of abnormal blood vessel growth and leakage in wet AMD and DME. Ang-2 destabilizes blood vessels and can exacerbate VEGF-A signaling. By blocking both targets, faricimab is designed to provide a more comprehensive approach to managing these conditions [3].
What are the clinical trial results for faricimab?
Clinical trials have demonstrated the efficacy and safety of faricimab in treating wet AMD and DME. In studies for wet AMD, faricimab showed non-inferiority to aflibercept in terms of visual acuity gains, with patients treated with faricimab requiring fewer injections over the treatment period [3]. Similar positive outcomes have been observed in trials for DME, where faricimab demonstrated significant improvements in visual acuity and retinal structure [3].
Are there biosimilars for faricimab?
As of now, there are no approved biosimilars for faricimab. The development of biosimilars can only occur after the relevant patents expire and market exclusivity periods end. Given the patent expiration date, any potential biosimilar development would be several years away [1][2].
What are the next steps for faricimab patents?
Patents can face legal challenges, and their terms can be affected by various factors, including patent term extensions (PTE) or adjustments. While U.S. Patent No. 10,975,250 B2 is expected to expire in 2038, it is possible that patent holders may seek extensions based on regulatory review periods, or that competitors might challenge the patent's validity [1][2].
---
Sources:
[1] US Patent 10,975,250 B2 - Google Patents: https://patents.google.com/patent/US10975250B2/en
[2] Patent Term of Utility Patents: https://www.uspto.gov/patents/basics/patent-term-utility-patents
[3] Genentech - Faricimab: https://www.gene.com/medicines/ophthalmology/faricimab